2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.067 Xiao Hu NACLC23 Abstract

PP01.067 Xiao Hu NACLC23 Abstract

Pdf Summary

Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment of lung cancer, but they are also known to cause immune-related adverse effects (irAEs). This study aimed to identify clinical predictors of irAEs and determine the impact of irAEs on the prognosis of lung cancer patients.<br /><br />The researchers analyzed the data of 125 lung cancer patients who started ICIs between October 2018 and September 2021. They extracted patient information, disease characteristics, treatment history, and outcomes from electronic health records. Statistical tests were used to compare patients who experienced irAEs with those who did not, and logistic regression and Cox regression were performed to identify risk factors for irAEs and assess their impact on overall survival (OS), respectively.<br /><br />Out of the 125 patients, 39 experienced 50 irAEs. The most common irAEs were endocrinopathies, pneumonitis, and dermatitis. Patients who developed irAEs were younger at the start of ICI treatment and more likely to have small cell lung cancer (SCLC) and less advanced disease stage.<br /><br />In the logistic regression analysis, SCLC and PDL1 positivity were significant risk factors for irAEs, while age showed borderline significance. However, the occurrence of irAEs did not significantly affect OS in both the log-rank test and Cox regression analysis. Factors such as sex, autoimmune disease, PDL1 positivity, and concurrent steroid use were also considered but did not significantly impact the development of irAEs.<br /><br />In conclusion, this real-world study suggests that lung cancer patients with SCLC, PDL1 positivity, and younger age are more likely to experience irAEs. Importantly, the development of irAEs does not seem to have a negative impact on the overall survival of lung cancer patients. Further research is needed to validate these findings with larger sample sizes.

Keywords

immune checkpoint inhibitors

lung cancer treatment

immune-related adverse effects

clinical predictors

prognosis

electronic health records

endocrinopathies

pneumonitis

dermatitis

risk factors